Department of Radiation Medicine
Senior Research Scientist
- Undergraduate: BS, Chemistry, Aristotelian University of Thessaloniki (Greece)
- Graduate: PhD, Organic Chemistry, Aristotelian University of Thessaloniki
- Post-graduate: Organic Chemistry, Princeton University and University of Pittsburgh
The development of hypoxia-activated agents as potential anticancer/antimetastatic drugs alone or in combination with radiotherapy, chemotherapy, radioimmunotherapy and for gene-directed enzyme prodrug therapy approach. The development of novel antitubercular, antifungal and antiparasitic agents. In particular I am interested in the treatment of latent tuberculosis and neglected tropical diseases (Chagas, African trypanosomiasis, Malaria and Leishmania).
- Assistant Professor, Chemistry (tenure track): Aristotelian University of Thessaloniki (1989-1990)
- Research Instructor: University of Pittsburgh, Radiation Oncology (1989-1992)
- Research Associate Professor: Northwestern University, Feinberg School of Medicine (1996-2008)
- Senior Research Scientist: Northshore University Healthsystem, Dept. of Radiation Medicine (1992-present)
Honors and Awards
- (1974-1978) The National Institute Scholarship (Greece)
- (1980-1984) The National Institute Scholarship (Greece)
- (1998-2001) NCI-RAID Award
- (2009-2012) NIH Challenge Grant: 1R01AI082542 – 01, Subaward No: RU374-063/4693578
- American Chemical Society
- International Society of Heterocyclic Chemistry
- Greek Chemical Society
- American Association for Cancer Research
- Radiation Research Society
- Robert H. Lurie Comprehensive Cancer Center
- AACR-Women in Cancer Research (WICR)
- Chemistry in Cancer Research Working Group (CCRWG)
- The Women Faculty Organization at NWU (WFO)
- European Association for Cancer Research (EACR)
- New York Academy of Sciences (NYAS; by invitation)
- Member of the Editorial Board of Anticancer Drugs
- Invited Speaker and Session Chairperson: 7th International Conference of Anticancer Research, Corfu Greece, 25-30 October 2004.
- Member of the Organizing Committee, Session Chairman and Invited Speaker: 8th Int. Conference of Anticancer Research , Kos, Greece, October 17-22, 2008.
- Invited speaker in the NY Academy of Sciences symposium on March 14, 2012, entitled: ‘Therapeutic and Diagnostic Modalities Targeting Hypoxia in Cancer.’
- Invited (and accepted the invitation) by the State Scholarships Foundation of Greece to be an evaluator of candidates that will apply for a scholarship for a Master or Doctoral Degree in Biosciences or Chemistry fields for the academic years 2011-2012 and 2012-2013. This act is materialized in the framework of the Operational Programme “Education and Lifelong Learning” and is co-financed by the European Union (European Social Fund – ESF) and by public recourses.
- Invited to be a Chief Editor for New journals in Biological Sciences by Mehta Press.
- Invited Speaker of the Target Meeting 2nd world drug discovery online conference held on October 16-18, 2012.
Publications in Peer-Review Journals:
- Papadopoulou M, Spyroudis S, Varvoglis A. 1,3- Oxathiolene-2-thiones from the Reaction of Carbon Disulfide with Zwitterionic Iodonium Compounds. J. Org. Chem., 50, 1509-1511,1985.
- Kokkinidis G, Papadopoulou M and Varvoglis A. Electrochemical Reduction of [Bis(Acyloxy)iodo]Arenes. Electrochemica Acta, 34, 133-139, 1988.
- Papadopoulou MV, Epperly MW, Shields DS and Bloomer WD. Radiosensitization and Hypoxic Cell Toxicity of NLA-1 and NLA-2, Two New Bioreductive Compounds. Jap. J. Cancer Res., 83 (4), 410-414, 1992.
- Papadopoulou MV, Miller A, Seskey T, Epperly MW and Bloomer WD. Potentiation of antineoplastic drugs in vitro and in vivo by DNA intercalating bioreductive agents. Radiat. Oncol. Invest. , 1, 206-217, 1993.
- Papadopoulou MV, Goswami S and Hamilton AD. Synthesis of Artificial Receptors as Potential Candidates for Recognition and Binding of Pterin Analogs. J. Heterocyclic Chem., 32 , 675-681, 1995.
- Papadopoulou MV, Ji M and Bloomer WD. THNLA-1 as radio/chemosensitizer of EMT-6 tumors in mice. Br. J. Cancer 74(Suppl. XXVII) S267-S270, 1996.
- Papadopoulou MV, Ji M and Bloomer WD. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int. J. Radiat. Oncol. Biol. Phys. 42, 775-779, 1998.
- Papadopoulou MV, Ji M, Rao MK,Bloomer WD. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol. Res. 12, 185-192, 2000.
- Papadopoulou MV, Ji M, Bloomer WD. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and Tirapazamine against EMT6 tumors in mice. Cancer Chem. Pharmacol. 48(2): 160-168, 2001.
- Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh J, Papadopoulou M, Bloomer WD, Goldenberg DM. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int. J. Cancer , 94: 564-571, 2001.
- Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG. Therapeutic advantage from combining Paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chem. Pharmacol. 50: 501-508, 2002.
- Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J. Exp. Ther. Oncol. 2(5):298-305, 2002.
- Papadopoulou MV, Ji M, Rao MK and Bloomer WD. Reductive Activation of the Nitroimidazole-based Hypoxia-Selective Cytotoxin NLCQ-1 (NSC 709257). Oncology Research-AntiCancer Drug design 14: 21-29, 2003.
- Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug [Review]. Clinical Cancer Research 9: 5714-5720, 2003.
- Papadopoulou MV, Rosenzweig HS, Bloomer WD. Synthesis of a Novel Nitroimidazole-spermidine Derivative as a Tumor-targeted Hypoxia-selective Cytotoxin. Bioorganic & Medicinal Chemistry Letters, 14: 1523-1525, 2004.
- Papadopoulou MV, Rosenzweig HS, Bloomer WD. Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers. Bioorganic & Medicinal Chemistry Letters, 14: 1519-1522, 2004.
- Papadopoulou MV, Bloomer WD. Exploiting Hypoxia in Solid Tumors with DNA-targeted Bioreductive Drugs. Drugs of the Future, 29(8):807-819, 2004.
- Rosenzweig, H.S., Papadopoulou, M.V. and Bloomer, W.D. Interaction of Strong DNA-intercalating Bioreductive Compounds with Topoisomerases I and II. Oncol. Res. 15:219-231, 2005.
- Papadopoulou MV, Bloomer WD, Hollingshead MG. NLCQ-1 (NSC 709257) in Combination with Radiation Against Human Glioma U251 Xenografts. Anticancer Res. 25(3):1865-1870, 2005.
- Papadopoulou MV, Pouremad R, Bloomer WD, Wyrwicz A. Novel Non-invasive Probes for Measuring Tumor-hypoxia by 19F-Magnetic Resonance Spectroscopy (19F-MRS). Studies in the SCCVII/C3H Murine Model. Anticancer Res. 26(5): 3259-3264, 2006.
- Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG. Advantage in Combining NLCQ-1 (NSC 709257) with Radiation in Treatment of Human Head and Neck Xenografts. Radiation Res. 168:65-71, 2007.
- Papadopoulou MV, Bloomer WD, McNeil MR. NLCQ-1 and NLCQ-2, Two New Agents with Activity Against Dormant Mycobacterium Tuberculosis. Int. J. Antimicrobial Agents 29:724-729, 2007.
- Papadopoulou MV, Bloomer WD. NLNQ-1, a 2-[3-(2-nitro-1-imidazolyl)-propylamino]-3-chloro-1,4-naphthoquinone as a hypoxia-selective cytotoxin and radiosensitizer. In Vivo, 22: 285-288, 2008 (Invited).
- Cowen RL, Garside EJ, Fitzpatrick B, Papadopoulou MV, Williams KJ. Gene therapy approaches to enhance bioreductive drug treatment. Br. J. Radiol. 81: S45-S56, 2008.
- Papadopoulou MV, Bloomer WD. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore. Anti-cancer Drugs 20(6):493-502, 2009.
- Papadopoulou MV, Bloomer WD, Torti VR, Page JG. IND-directed, five-day repeat dose toxicity study of NLCQ-1 (NSC 709257) administered with or without Taxol® in Sprague Dawley rats. Basic & Clinical Pharmacology & Toxicology, 106:497-504, 2010.
- Papadopoulou MV, Bloomer WD, Torti VR, Page JG. IND-Directed Toxicology and Pharmacokinetic Study of NLCQ-1 (NSC 709257) in Beagle Dogs. Basic & Clinical Pharmacology & Toxicology 106:511–522, 2010.
- Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Hogg A, Julian PJ, Price PM, Stratford IJ, Bloomer WD, Papadopoulou MV, Williams KJ. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. Br. J. Cancer 103:201-208, 2010.
- Papadopoulou MV, Ji M, Bloomer WD. Hypoxia-Dependent Retinal Toxicity of NLCQ-1 (NSC 709257) in BALB/c Mice. Comparison with Tirapazamine. Basic & Clinical Pharmacology & Toxicology, 108, 396-399, 2011.
- Papadopoulou MV, Bourdin B, Bloomer W, Prasittichai C, Brun R, Kaiser M, Torreele E, Wilkinson S, McKenzie C. Novel 3-Nitro-1,2,4-triazole-based Aliphatic and Aromatic Amines as anti-Chagasic Agents. J. Med. Chem. 54(23), 8214-8223, 2011. DOI: 10.1021/jm201215n.
- Papadopoulou MV, Bloomer W, Rosenzweig HS, Chatelain E, Kaiser M, Wilkinson S, McKenzie C, Ioset J-R. Novel 3-Nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential anti-trypanosomal agents. J. Med. Chem 55(11), 5554-5565, 2012. DOI: 10.1021/jm300508n.
- Li L-P, Franklin T, Du H, Papadopoulou-Rosenzweig M, Carbray J, Solomon R, Prasad PV. Intrarenal oxygenation by Blood Oxygenation Level-Dependent MRI in contrast nephropathy model: effect of the viscosity and dose. JMRI 36:1162-1167, 2012.
- Buchanan-Kilbey G, Djumpah J, Papadopoulou MV, Bloomer WD, Hu L, Wilkinson SR, Ashworth R. Evaluating the developmental toxicity of trypanocidal 1 nitroaromatic 2 compounds on zebrafish. Acta Tropica 128:701-705,2013.
- Papadopoulou MV, Bloomer WD, Rosenzweig HS, Ashworth R, Wilkinson SR, Kaiser M, Andriani G, Rodriguez A. Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: In vivo studies. Future Med. Chem. 5(15):1763-1776, 2013 (Invited).
- Papadopoulou MV, Bloomer WD, Rosenzweig HS, Chatelain E, Ioset J-R. Novel 3-Nitro-1H-1,2,4-triazole-bearing Piperazines and 2-Amino-benzothiazoles as anti-Chagasic Agents. Bioorg. Med. Chem. 21: 6600–6607, 2013.
- Li L-P, Lu J, Zhou Y, Papadopoulou MV, Franklin T, Bokhary U, Solomon R, Sen A, Prasad PV. Evaluation of intrarenal oxygenation in iodinated contrast-induced acute kidney injury - susceptible rats by Blood Oxygen Level-Dependent Magnetic Resonance Imaging. Invest. Radiol. 49(6): 403-410, 2014.
- Li L-P, Thacker J, Lu J, Franklin T, Zhou Y, Papadopoulou M, Solomon R, Prasad PV. Efficacy of preventive interventions for iodinated contrast-induced acute kidney injury evaluated by intrarenal oxygenation as an early marker. Invest. Radiol. 2014.
Peer Review Service:
- Reviewer of Scientific Journals: Cancer Research, Molecular Cancer Therapeutics; Clinical Cancer Research; Anti-Cancer Drugs; Bioorganic & Medicinal Chemistry Letters; Bioorganic & Medicinal Chemistry; Expert Opinion on Therapeutic Patents; European Journal of Inorganic Chemistry; European Journal of Organic Chemistry; Medical Science Monitor; Drug Design and Discovery; Technology in Cancer Research and Treatment; BioMed Central (BMC Cancer); British Journal of Radiology; Australian Journal of Chemistry; International Journal of Antimicrobial Agents; Eur. J. of Medicinal chemistry; Medicinal Chemistry (Bentham); British J. Cancer; International Journal of Radiation Biology; Investigational New Drugs; Molecular Pharmaceutics (ACS publication); Neoplasia; Future Medicinal Chemistry; Drug Design, Development and Therapy; Research and Reports in Medicinal Chemistry; Research and Reports in Tropical Medicine (Dovepress); J. Med. Chem. (ACS); J. Biolog. Phys.; Mini Reviews in Medicinal Chemistry; Medicinal Chemistry Communications; RSC Advances; DARU Journal of Pharmaceutical Sciences; American Journal of Epidemiology and Infectious Disease; Molecules.
- Reviewer of a grant proposal, submitted to the Istituto Toscano Tumori (ITT), Italy.
- THNLA-1, a DNA-targeted bioreductive agent as a chemosensitizer in vitro and in vivo. 5th International Conference of Anticancer Research, Corfu, Greece, October 17-22, 1995.
- Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine. Workshop: Bioreductive Drugs: Update and New Directions. July 19, 1999 (11th International Congress of Radiation Research. Dublin, Ireland, July 18-23, 1999).
- NLCPQ-1 and NLCQ-1, two novel bioreductive compounds with potential for development as adjuvants to (radio/chemo)therapy in the clinic. NCI/NIH, Fairview Center, Frederick, MD, January 5, 2000.
- NLCQ-1 (NSC 709257): An Overview. National Cancer Institute, Rockville, MD. February 13, 2004.
- NLCQ-1 (NSC 709257): Exploiting Hypoxia with a Weak DNA-intercalating Bioreductive Drug. 7th International Conference of Anticancer Research, 25-30 October 2004, Corfu Greece.
- NLCQ-1 (NSC 709257): Exploiting Hypoxia with a Weak DNA-intercalating Bioreductive Drug. Adherex Technologies Inc. 4620 Creekstone Drive, Durham, NC 27703. May 5, 2006, 8:30am-12:30pm.
- NLCQ-1 (NSC 709257): A Weak DNA-intercalating Bioreductive Drug. New Prospects. 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece.
- Nitro- and Non-Nitro- triazoles for Chagas. Chagas Drug Discovery Consortium. The Coverdell Center, CTEGD, University of Georgia, Athens, GA, December 18, 2009.
- The development of novel nitrotriazole-based compounds as antichagasic agents. 2010 Chagas Drug Discovery Consortium. Hilton Hotel, Rm 301, 255 Courtland St NE, Atlanda, GA, November 3, 2010.
- NLCQ-1 (NSC 709257): A Weak DNA-intercalating Bioreductive Drug. An Overview and New Prospects. The University of Chicago, Department of Radiation and Cellular Oncology. Faculty Research Lecture Series. Conference Room-DCAM 1333. November 17, 2011.
- NLCQ-1 (NSC 709257): A Weak DNA-intercalating Bioreductive Drug. An Overview and New Prospects. Therapeutic and Diagnostic Modalities Targeting Hypoxia in Cancer. The New York Academy of Sciences, 7 World Trade Center 250 Greenwich St., 40th Floor, New York, NY 10007-2157. March 14, 2012 (12:30-6:00 PM).
- The development of novel nitrotriazole-based compounds as antichagasic agents: In vitro and in vivo studies. 2012 Chagas Drug Discovery Consortium. GSK Campus, Tres Cantos, Madrid, Spain, April 19-20, 2012.
- Bioreductive compounds and the challenge of hypoxia in cancer therapy. Northshore Symposium on Investigator-Initiated Research, Frank Auditorium, Evanston Hospital, October 3, 2012, 4:20-4:40 p.m.
- Bioreductive Drugs and the Challenge of Hypoxia in Cancer Treatment. TargetMeeting: 2nd World Drug Discovery Online Conference, October 16-18, 2012. October 18, 2:30-3:00 p.m.
- Recent developments of novel nitrotriazole-based compounds as potential antichagasic agents. Chagas Drug Discovery Consortium Meeting, 2013, Nov. 13, Washington DC.
- Acridine-Intercalator Based Hypoxia Selective Cytotoxins. Papadopoulou-Rosenzweig MV. and Bloomer WD. US Patent; Issued: March, 15, 1994, # 5,294,715.
- DNA-affinic Hypoxia Selective Cytotoxins. M.V. Papadopoulou-Rosenzweig and W.D. Bloomer. US Patent; Issued: February 11, 1997, # 5,602,142
- DNA-affinic Hypoxia Selective Cytotoxins (Divisional of No: 5,602,142). M.V. Papadopoulou-Rosenzweig and W.D. Bloomer. US Patent; Issued: September 28, 1999. # 5,958,947
- Method of treating latent tuberculosis. Maria V. Papadopoulou and W.D. Bloomer. US Provisional Patent Application, No: 28493/41859 (9-1-2006).
- E.C. Taylor, Z.-y. Chang, P. M. Harrington, J. M. Hamby, M. Papadopoulou, J. C. Warner, G. S. K. Wong, C.-m. Yoon, and C. Shih. New Synthetic Studies on Deazafolates. In Chemistry and Biology of Pteridines, H.-Ch. Curtius, S. Ghisla and N. Blau, eds., Walter de Gruyter & Co., Berlin, New York, 1989, pp. 987-994.